ResearchInCh
The United States has the largest pharmaceutical industry in the world. In 2007, its pharmaceutical revenue totaled at US$ 315 billion.
In the past decades, the structure of American pharmaceutical industry has changed dramatically caused by the aging of population, the emerging of bio-pharmaceutical technology and fierce global competition. The key players in the United States including Pfizer, GlaxoSmithKline, Johnson & Johnson, Merck, etc.
American pharmaceutical companies paid great attention to R & D due to the free market competition and patent protection of new medicines in the US. Since the year of 2000, the pharmaceutical R & D expenditure has been maintaining an increase, even in 2008, impacted by the global financial crisis, the pharmaceutical R & D expenditure totaled at US $65.2 billion, up 3.16% of last year.
There are 2,900 drugs currently in research in US, among which 750 are anticancer drugs, 312 drugs are for heart diseases, 150 are diabetes drugs and 109 are AIDS drugs, the rest 91 drugs are for the Alzheimer and senile dementia diseases.
In 2009, the sales growth of drugs in the United States is expected to around 1% ~ 2%. The growth of biotechnology, special drugs and generic drugs will be higher than the average.
The report focus on the 30 pharmaceutical companies in the United States, including their profiles, revenue and profit, as well as their products, market distribution and development strategies.
Table of Contents
1. Current Status and Prospects of US Pharmaceutical Industry
2. Pfizer Inc
3. Glaxo Smith Kline
4. Merck &Co.
5. Johnson & Johnson
6. Eli Lilly and Co
7. EpiCept Corporation
8. Schering Plough Corp
9. Forest Laboratories Inc
10. Mylan Inc
11. Herbalife Ltd
12. King Pharmaceuticals Inc
13. NBTY Inc
14. Perrigo Co
15. Life Technologies Corp
16. Sepracor Inc
17. Endo Pharmaceuticals Holdings Inc
18. Warner Chilcott Ltd
19. Par Pharmaceutical Companies Inc
20. Valeant Pharmaceuticals International
21. Chattem Inc
22. Prestige Brands Holdings Inc
23. Medicines Co
24. Techne Corp
25. Cambrex Corp
26. Allion Healthcare Inc
27. Salix Pharmaceuticals Ltd
28. PDL BioPharma Inc
29. Albany Molecular Research Inc
30.Enzon Pharmaceuticals Inc
31. AmerisourceBergen Corp
Selected Charts
Profit Pool of world’s pharmaceutical sector，2007
2007 Top companies by U.S Sales
Biopharmaceutical Companies’ investment in R&D, 1980-2008
R&D as a Percentage of Sales, PhRMA Member Companies, 2000–2008
Number of Compounds in Development, by Region*
Domestic R&D Source, PhRMA Member Companies:2007
Biologics and Biotechnology R&D, PhRMA Member Companies:2007
2007 Channel Distribution by U.S Sales
Pfizer Revenue by Business Segments，2006-
Change in Pfizer’s Revenues by Segment and Geographic Area, 2006-2008
Revenue and net profit of Pfizer Inc, 2004- 2008
Analysis of the Consolidated Statement of Income of Pfizer, 2006-2008
2008 Turnover summary，by segment
GSK 2008 Turnover summary，by geography
GSK Pharmaceutical turnover analysis，2007-
GSK Pharmaceutical key growth products，2007-
GSK Market share growth in Emerging Markets, 2008
GSK Product pipeline，2007-
Revenue and net profit of GSK, 2004- 2008
Financial performance of GSK, 2007-2008
Product sales of Merck, 2006-2008
Merck patent protection products
Research pipeline of Merck as of Feb.15, 2009
Revenue and net profit of Merck, 2004- 2008
Sales of Johnson & Johnson, 1998-2008
Sales of Johnson & Johnson by Geographic Region, 1998-2008
Consumer segment sales of Johnson & Johnson, 2008
Consumer segment sales of Johnson & Johnson, 2006-2008
Pharmaceutical segment sales of Johnson & Johnson, 2008
Major Pharmaceutical Product revenues of Johnson & Johnson, 2006-2008
Medical Devices& Diagnostics segment of Johnson & Johnson, 2008
Major Medical Devices& Diagnostics Franchise sales of Johnson & Johnson, 2006-2008
R&D expense of Johnson & Johnson, 2006-2008
Johnson & Johnson Operating profit by segment, 2007-2008
Eli Lilly Eight Products Exceed $1 Billion in Net Sales, FY2008
Eli Lilly net sales activity of major products in 2007 compared with 2006
Eli Lilly products launched this decade
Research and Development investment increasing, 2004-2008
Revenue and net profit of Eli Lilly, 2004- 2008
Return on Assets and shareholders’
Development Pipeline of main products of EpiCept
Revenue and net profit of EpiCept, 2004- 2008
Net sales and Profit by segment, 2006-2008
Prescription pharmaceuticals sales of Schering Plough, 2007-2008
Revenue of Schering Plough by region
Net sales and long-lived assets of Forest, 2006-2008
Net sales by therapeutic class of Forest
Pipeline snapshot of Forest
Strategically focused of Forest
Revenue and net profit of Forest ，2004-2008
Financial highlights of Forest，2004-
Net sales and long-lived assets of Forest, 2006-2008
Comparison of 5 Year Cumulative Total Return, 2003-2008
Revenue composition of Mylan, 2007-2008
Mylan’s global market leadship, 2008
Significant operational properties of Mylan
Revenue and net profit of Mylan，2004-
Comparison of cumulative total returns of Mylan’s Common Stock, the Standard & Poor’s 500 Composite Index and the Dow Jones U.S. Pharmaceuticals Index, 2003-2008
Sales of Herbalife by Geographic Region, 2007-2008
Sales by product category, 2007-2008
Revenue and net profit of Herbalife, 2004-2008
Comparison of cumulative total returns of Herbalife’s Common Stock, S& P 500 Composite Index and the Peer Index, 2004-2008
Revenue and net profit of King Pharmaceuticals, 2004-2008
Operating segments of NBTY, 2006-2008
Revenue and net profit of NBTY, 2004-2008
Comparison of 5 year cumulative total return among NBTY, Inc., NYSE Composite Index and The NYSE Care Index ,2003-2008
Perrigo revenue by country and by segment, 2008
Manufacturing scale of Perrigo, 2008
Sales, volumes and profits of Perrigo by category,2008
Updated category of Perrigo, 2008
Performance of Generic segment of Perrigo, 2008
Performance of API segment of Perrigo, 2008
R&D of Perrigo, 2004-2009
Revenue and net profit of Perrigo, 2004-2008
Perrigo financial performance,2003-
Revenue by geography of Life Technologies, 2008
Revenue by end markets of Life Technologies,2008
Basic data of Life Technologies, 2008
Revenue and net profit of Life Technologies,2004-
Comparison of 5-year cumulative total return among Life Technologies, NASDAQ market Index and NASDAQ Pharmaceutical Index, 2003-2008
Research and development pipeline of Sepracor,2008
Revenue and net profit of Sepracor，2004-
Product portfolio of Endo, 2008
Endo’s net sales by product category, 2006-2008
Revenue and net profit of Endo，2004-
Comparison of 5-year cumulative total return among Endo, NASDAQ market Index and NASDAQ Pharmaceutical Index, 2003-2008
Warner Chilcott’s revenues by product classes, 2006-2008
Revenue and net profit of Warner, 2005-2008
Revenue and net profit of Par，2004-2008
Product portfolio of Valeant
Revenue breakout of Valeant，2008
Valeant revenue by product, 2007-2008
Valeant revenue of branded product, 2006-2008
Revenue and net profit of Valeant，2004-
Domestic net sales of Chattem, 2007-2008
Geographical segment information of Chattem, 2006-2008
Revenue and net profit of Chattem, 2004-2008
Prestige net revenue by segments, 2008
Revenue and net profit of Prestige, 2004-2008
Revenue and net profit of Medicines, 2004-2008
Products introduced by Techne, FY1989-2008
Results of Operations of Techne，2006-
Revenue and net profit of Techne, 2004-2008
Cambrex Gross sales by product groups, 2006-2008
Cambrex Gross sales by district, 2006-2008
......
For details of this report please visit http://www.researchinchina.com/
Photo:
http://www.prlog.org/
